New treatment could stop brain damage caused by dementia – study

Scientists have discovered that sodium selenate may be the answer to the dementia treatment sought by medical professionals. This new drug could provide a crucial treatment for patients with early stages of behavioral variant frontotemporal dementia, which is more common in people aged 65 and under.

This variant of dementia is the second most common form in people under the age of 60. According to a peer-reviewed study conducted by scientists at Australia’s Monash University, this treatment is successful in stabilizing escalating behavioral problems caused by frontotemporal dementia before it occurs.

This breakthrough drug could also dramatically slow brain shrinkage resulting from the disease. The second clinical trial of sodium selenate showed the drug may have an impact on slowing cognitive decline and brain damage that accompanies many forms of dementia, such as Alzheimer’s disease.

How is this form of dementia different from others?

Behavioral variant frontotemporal dementia (bvFTD) is known for its rapid progression. Although many people associate dementia with the elderly, bvFTD can impact patients as young as 35 years old. Symptoms become evident in disruptive behaviors and unexpected personality changes. Once diagnosed, patients often survive for 5-7 years from initial diagnosis.

The University, in collaboration with the Royal Melbourne Hospital, the only hospital in the country working to eradicate non-genetic bvFTD and one of the very few in the world studying the subject, conducted several phases of trials. They found that sodium selenate is safe and well received by patients with this form of dementia, over a period of one year.

Important results from this study revealed that patients undergoing this treatment had no change in cognitive or behavioral symptoms.

According to researchers at Monash University, nearly half of recorded bvFTD cases result in brain damage due to protein buildup. Tau, the protein in question, has become a targeted research topic in the search for answers to reverse neurodegeneration.

Dr. Lucy Vivash, who led the clinical trials with Monash University’s Department of Neuroscience, the drug sodium selenate was instrumental in breaking down the tau protein. “We have already shown, in a phase 2 trial, that sodium selenate given to patients with mild to moderate Alzheimer’s disease leads to less neurodegeneration than in those without it,” he said. she declared.

Leave a Comment